Understanding Insurance Coverage & Cost-Share Assistance with Marissa Shackleton

April 29, 2020

What Infusion Operators Should Know about Medically Integrated Dispensing

November 17, 2026

NICA Letter Supporting Pharmacy Benefit Manager Reform in the Consolidated Appropriations Act of 2026

January 21, 2026

Legislative Comment

In January 2026, NICA urged congressional leadership to advance pharmacy benefit manager (PBM) reform provisions included in the Consolidated Appropriations Act of 2026. NICA highlighted concerns about PBM consolidation, rising patient out-of-pocket costs, and anticompetitive business practices. The letter supported reforms to increase pricing transparency, require manufacturer rebates to be passed on to employers, and eliminate compensation structures that incentivize higher drug prices.


January 21, 2026

The Honorable Mike Johnson   
Speaker
U.S. House of Representatives
Washington, DC 20515  
The Honorable John Thune
Majority Leader U.S. Senate Washington, DC 20510  
The Honorable Hakeem Jeffries
Minority Leader
U.S. House of Representatives  
Washington, DC 20515
The Honorable Chuck Schumer Minority Leader U.S. Senate Washington, DC 20510

Re: Consolidated Appropriations Act of 2026 – Support PBM Reform Provisions

Majority Leader Thune, Speaker Johnson, Leader Schumer, and Leader Jeffries:

The National Infusion Center Association (NICA) is a nonprofit organization formed to support non-hospital, community-based infusion centers caring for patients in need of provider-administered medications. To improve access to medical benefit drugs that treat complex, rare, and chronic diseases, we work to ensure that patients can access these drugs in safe, more efficient, and cost-effective alternatives to hospital care settings. NICA supports policies that improve drug affordability for beneficiaries, increase price transparency, reduce disparities in safety across care settings, and foster patient access to the highest-quality, lowest-cost setting.

NICA strongly supports policies that address the anticompetitive and harmful business practices of Pharmacy Benefit Managers (PBMs) and urges Congress to advance the PBM reform policies currently included within the Consolidated Appropriations Act of 2026, which will protect patients and ensure access to care.

Over the last decade, the PBM industry has seen considerable consolidation, which was recently noted by the Federal Trade Commission. [1] The contractual posture that formerly existed when the insurer and the PBM were distinct entities has disappeared through mergers – Express Scripts is a subsidiary of Cigna, CVS Caremark is a subsidiary of CVS Health, and OptumRX is a UnitedHealth Group subsidiary. Historically, insurers and employers were considered clients of PBMs. However, due to extensive vertical integration within the industry, the relationship between insurers and PBMs has evolved to a mutualistic relationship. Together, these three PBMs cover over 260 million patients, amounting to control over three quarters of the prescription drug market in the United States.[2] 

Consolidation in the market has made it difficult to negotiate with these entities.  More concerning is the impact on patients, who find themselves vulnerable when their insurance providers and PBMs prioritize profits over patient savings. While PBMs excel at securing discounts, these cost reductions rarely translate into lower out-of-pocket expenses for patients.  The drug pricing and premium trends over the last decade demonstrate that whatever savings PBMs negotiate are mostly absorbed by the PBMs themselves – not the patient. In fact, for every rebated dollar, the list price of the medication increases by $1.17.[3] That hurts the patient, who typically pays coinsurance on the list price before rebates are applied.

This is why comprehensive PBM reform is needed now.  NICA supports the following PBM reform provisions included within the Consolidated Appropriations Act of 2026:

  • Require manufacturer rebates to be passed on directly to the employer, offering immediate savings for employee health plans
  • Require PBM payments to only be derived from flat dollar amounts and not based on coverage or formulary placement
  • Improve transparency by requiring mandatory reporting

Some manufacturers offer significant rebates for their medications.  Unfortunately, most price concessions do not translate into savings for employers or patients, but are retained by the PBM itself.[4]  Thus, these rebates currently fail to have the full impact on patient out-of-pocket costs.  Instead, NICA supports policies that allow these rebates to be passed on directly to the employer so they experience immediate savings that can in turn be passed on to their employees through more robust coverage or cheaper health plan contributions. 

Several “transparent” PBMs have disrupted the market by adjusting their fee structures to collect a flat dollar amount instead of a percentage of the drug’s list price.  This removes the incentive for PBMs to prefer high-cost drugs over lower cost medications simply due to the PBM’s percentage-based compensation.  NICA supports policies that require PBMs to remove coverage determinations and formulary placement from the PBM’s fee structure and instead base compensation on flat dollar amounts.

It is very clear that PBMs and their vertically integrated subsidiaries operate in a vacuum in which none of the other parties– including ambulatory infusion centers – have access to information on how these drug pricing decisions are made.  With an entirely consolidated vertical supply chain, tracing money within the business model becomes nearly impossible. Improved reporting and transparency are necessary to improve our understanding of drug prices and should be included within any PBM reform package.

The current pricing system is not serving patients in need of prescription drugs, and it is particularly harmful for patients on infused specialty medications that can be quite expensive due to their complexity.  The business practices of pharmacy benefit managers are driving higher out-of-pocket costs for patients, formulary design that encourages the use of expensive drugs over lower-cost alternatives, and utilization management that results in delayed and even denied access to care.  NICA urges Congress to address these harmful and anticompetitive business practices within the Consolidated Appropriations Act of 2026, and protect patients who deserve lower out-of-pocket costs, greater drug access and improved transparency.

Thank you for the opportunity to comment on this important issue. Should you have any questions, please contact [email protected].

Sincerely,

Brian Nyquist, MPH

Chief Executive Officer

National Infusion Center Association


[1] Federal Trade Commission, “Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies” (July 2024).

[2] Health Affairs, Health Policy Brief, “Pharmacy Benefit Managers” (Sept. 14, 2017).

[3] The Association Between Drug Rebates and List Prices, Neeraj Sood, PhD, Rocio Ribero, PhD, Martha Ryan, and Karen Van Nuys, PhD, University of Southern California, Leonard D. Schaeffer Center for Health Policy & Economics (Feb. 11 2020).

[4] Annals of Health Law, “Squeezing the Middlemen: Ending Underhanded Dealing in the Pharmacy Benefit Management Industry Through Regulation” 20 Annals of Health Law 77, 82 (2011).

Related Posts

October 5, 2026

NICA Response to Senate Finance Committee’s Request for Information Regarding “Health Coverage that Works for Everyone”

 In October 2026, NICA submitted comments to the Senate Finance Committee on addressing insurance practices that create barriers to necessary medical care. NICA highlighted several policies that […]
August 26, 2026

NICA Comments Regarding Senator Cassidy’s Discussion Draft of the 340B Drug Pricing Integrity and Affordability for Patients Act

In August 2026, NICA submitted comments to Senator Bill Cassidy, MD (R-La.) regarding his discussion draft of the 340B Drug Pricing Integrity and Affordability for Patients […]
August 21, 2026

NICA Response to House Doc Caucus’ Request for Information Regarding “Strengthening theMedicare Physician Payment

In August 2026, NICA submitted comments to the House Republican and Democratic Doctors Caucuses on ways to strengthen Medicare’s physician payment system. NICA emphasized that more stable […]
✕

Login

When you login, you will be directed to admin.infusioncenter.org. When you get there:

  • Enter the email address that was used to claim your center in the Infusion Center Locator or
  • If you are looking to add your infusion center (i.e. it does not already exist as an unclaimed location in the locator), enter the email you would like to be associated with the location.

You will receive an email with a link to click that will log you into the resources section of the locator, which includes your claimed and/or activated infusion center(s).

Please note: you will have to enter your email each time as we no longer have passwords for extra security. This login process is separate from the forum.

If you have questions about the email address associated with the location, how to add or claim a center, how to purchase a resource, etc., please email our Member Relations lead, Ashley Kana at [email protected].

✕

NICA